Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
Tesamorelin is a synthetic version of growth hormone-releasing hormone that the FDA has approved, as the Egrifta products, for one use, “the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy”, and that is promoted online far more widely, to people without HIV, for belly fat and anti-aging. Tested in people: in two randomized trials that analysed 806 adults with HIV, the original Egrifta was shown to shrink visceral fat (abdominal fat other than fat under the skin) on a CT scan by 20% and 12% more than placebo over 26 weeks; weight did not change, and the fat returned when treatment stopped. The evidence stops there: no trial has shown fewer heart attacks, less diabetes, longer life or weight loss; outside HIV the fat result is one unrepeated 60-person obesity trial; and compounded or “research” tesamorelin has not been studied in people.
This review is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Approved only as the Egrifta products, for “the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy”.
- Evidence in people
- Two main randomized trials, 806 adults with HIV: less visceral fat on CT, weight unchanged. Heart outcomes: not tested.
- The claim you’ve heard
- Belly-fat loss for anyone: outside HIV, one unrepeated 60-person trial. Label: “not indicated for weight loss management”.
- Doses tested in people
- 2 mg a day (original Egrifta) in approval trials. Current labels: 1.4 mg (Egrifta SV), 1.28 mg (Egrifta WR).
- Sport
- Prohibited at all times: named in class S2 of WADA’s 2026 and 2027 Prohibited Lists.
What tesamorelin is
Tesamorelin is a synthetic peptide: the full 44-amino-acid chain of human growth hormone-releasing hormone (GHRH), with a six-carbon chain added at one end “to extend its half-life while retaining its biological activity”, in the FDA’s words. It prompts the pituitary gland to release the body’s own growth hormone, which in turn raises a second hormone, IGF-1.
Three FDA-approved products contain it, all from Theratechnologies:
- Egrifta, the original, approved in 2010 and used in every trial behind the approval. The company says it “is no longer offered for sale in the United States”.
- Egrifta SV and Egrifta WR, later formulations with lower milligram doses. Neither was in those trials; their labels rest on the original’s trials plus comparisons of blood levels.
Also sold under the name, not FDA-approved and not studied in people: compounded tesamorelin, “research use only” tesamorelin sold online, and blends with ipamorelin, a different peptide.
Tesamorelin is not sermorelin and not CJC-1295: both are 29 amino acids long, and a study of one is not evidence for another. No form taken by mouth, by nose or under the tongue has been tested in people.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: the FDA-approved tesamorelin products on the market are Egrifta SV and Egrifta WR, approved to reduce excess abdominal fat in adults with HIV and lipodystrophy, not for weight loss. Since March 2020 Egrifta has been regulated as a biological product, a class the FDA says is not eligible for the exemptions federal law gives compounded drugs; compounded or “research” tesamorelin is not FDA-approved.
As of November 19, 2026, the FDA-approved tesamorelin products on the market are Egrifta SV and Egrifta WR, each “indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy”; each label says the product “is not indicated for weight loss management as it has a weight neutral effect.” On March 23, 2020, Egrifta’s approved application “was deemed to be a license for the biological product”, and the FDA says “Biological products are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FD&C Act”; a product sold as compounded or “research” tesamorelin is not FDA-approved, and the FDA’s August 2026 warning letters to online sellers called tesamorelin marketed “for research use only” one of several “unapproved new drugs”.
What the approval covers. The FDA’s Division Director wrote that the approval “is not an FDA endorsement of this endpoint as a validated surrogate for drug approval in other highly prevalent conditions (e.g., metabolic syndrome, obesity, atherosclerosis)” (the endpoint: visceral fat). Both labels add, in Egrifta WR’s words: “Long-term cardiovascular safety of EGRIFTA WR has not been established.”
Egrifta used for anything else is outside its label. Of such use the FDA says, in general, that providers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate”, but “FDA has not determined that the drug is safe and effective for the unapproved use.”
Compounding. Tesamorelin has 44 amino acids, and the FDA’s rule counts a chain “greater than 40 amino acids in size” as a protein, a kind of biological product. The FDA’s statements above are general: no FDA document we found applies them to compounded tesamorelin by name since 2020.
HHS’s draft peptide policy. The draft interim policy on peptide compounding that HHS (the federal department the FDA belongs to) announced on October 30, 2026 does not name tesamorelin, and tesamorelin is on none of the FDA’s compounding category lists.
“Research use only” products. Five FDA warning letters to online sellers, all dated August 24, 2026, name tesamorelin products, two of them blends with ipamorelin. One says that, whatever the labelling, “evidence obtained from your website establishes that your products are intended to be drugs for human use.”
Outside the United States. The European application was withdrawn in June 2012; at the time, the European Medicines Agency’s committee “was of the opinion that the benefits of Egrifta did not outweigh its risks.”
Sport. WADA’s 2026 and 2027 Prohibited Lists name tesamorelin in class S2, prohibited at all times.
Claims you’ll see, and why sources disagree
Pages about tesamorelin disagree for three reasons:
- They stretch one approval. “FDA-approved” is offered as reassurance for uses the approval does not cover: it covers one measurement, visceral fat on a scan, in adults with HIV and lipodystrophy.
- They carry results across groups. Outside HIV, the belly-fat claim rests on one trial, in 60 people chosen for low growth hormone.
- They read a scan as a health outcome. The FDA: “Egrifta is clearly effective on modifying a biomarker but what the clinical benefit is with this degree of VAT reduction is uncertain” (VAT is visceral fat).
Where this review says “not tested in people”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.
| Claim | Level of evidence | Verdict |
|---|---|---|
| Reduces visceral fat in adults with HIV and lipodystrophy | Tested in people: three randomized trials | Supported. The fat returns after stopping; no health benefit has been shown to follow. |
| Reduces belly fat without HIV | Tested in people: one trial, 60 obese adults with low growth hormone | Partly supported, by one trial never repeated. |
| Causes weight loss | Tested in people | Contradicted. The labels: “a weight neutral effect”. |
| Builds muscle; improves strength, performance or recovery | Tested in people: scans in HIV; a walk test in 22 adults without HIV | No evidence for strength, performance or recovery. Lean mass on a scan rose 1.3 and 1.2 kg in the HIV trials and fell after the switch to placebo; the walk test did not change significantly. |
| Sharpens thinking and memory | Tested in people: three trials | One positive trial in 152 older adults without HIV; a 22-person pilot, and a trial in HIV, found no significant difference. |
| Reduces liver fat | Tested in people with HIV: two small trials | Supported in HIV, on imaging. Without HIV: unpublished numbers, no statistical test. |
| Improves sleep, protects the heart or slows aging | Sleep: one 22-person pilot. Heart events, aging: not tested | No evidence. Sleep did not change significantly in the pilot. |
| Safer than growth hormone | No trial compares their long-term safety | Not established. The FDA found “similar side-effects (albeit attenuated) to that of rhGH” (growth hormone). |
| Works better with ipamorelin | Not tested, in people or animals | No evidence. |
What the evidence consists of
The developer, Theratechnologies, ran both phase 3 trials and nearly all the animal work. The independent published trials were funded by the US National Institutes of Health (one partly by the company), with company-supplied drug. Every result belongs to an Egrifta product. We read the phase 2 and 3 papers as abstracts; their figures come from those abstracts, the label and the FDA’s review.
Tested in people: adults with HIV
| Study | People | Design | What happened | Funding or limits |
|---|---|---|---|---|
| Phase 3, Study 1 (Falutz, 2007) | 412 with abdominal fat | Randomized, double-blind; 26 weeks | Visceral fat fell 31 cm² more than on placebo (95% CI 24 to 39): 20% | Sponsor’s trial; 80% completed |
| Phase 3, Study 2 (Falutz, 2010) | 404, same criteria | The same | 21 cm² more (95% CI 12 to 29): 12% | Sponsor’s trial; 74% completed |
| Extensions of both | 207 and 177 who finished on tesamorelin | Re-randomized to continue or switch to placebo; 26 weeks | Continuing held the loss; switching brought a regain of 25 and 24 cm² | Completers only |
| Phase 2 (Falutz, 2005) | 61 | Randomized; two doses or placebo; 12 weeks | Visceral-fat change “not significant versus placebo” | Sponsor’s trial |
| Stanley, 2014 | 50 with abdominal fat | Randomized, double-blind; 6 months | Visceral fat fell 42 cm² more than on placebo (95% CI 14 to 71) | NIH-funded; “preliminary study” |
| Stanley, 2019 | 61 with fatty liver | Randomized, double-blind; 12 months | Liver fat fell 4.1 percentage points more than on placebo (95% CI 0.7 to 7.6) | NIH-funded; senior author named on a patent application for this use |
| Ellis, 2025 | 73 with abdominal obesity and impaired thinking | Randomized, open-label; 6 months | No significant difference in thinking and memory (P=.673) | NIH-funded; no placebo |
Beyond the scan. In the phase 3 trials weight did not differ from placebo: −0.4 kg (95% CI −1.3 to 0.5) and 0.2 kg (−0.7 to 1.3), compatible with a small loss, no change or a small gain.
How the FDA read it. The reductions in visceral fat “were not accompanied by robust or consistent changes” in body image or blood fats (each differed from placebo in one trial and not the other). The FDA’s summary puts withdrawals for adverse events at 9.6% on tesamorelin and 6.1% on placebo.
Liver. In the 2019 trial, scarring (fibrosis) advanced in 2 people on tesamorelin against 9 on placebo (P=0.04), a secondary outcome; “Tesamorelin did not improve existing fibrosis”.
Tested in people: adults without HIV
| Study | People | Design | What happened | Funding or limits |
|---|---|---|---|---|
| Makimura, 2012 | 60 abdominally obese adults with reduced growth hormone; 36 finished | Randomized, double-blind; 12 months | Visceral fat fell 35 cm² more than on placebo (95% CI 12 to 58); no weight loss | NIH and Theratechnologies; never repeated |
| NCT03375788 (unpublished) | 51 adults with obesity and liver fat; 38 finished | Randomized, double-blind; 12 months | Median percent change in liver fat: −5.3 against +3.6 | Registry numbers only; no statistical test |
| Baker, 2012 | 152 adults aged 55 to 87 | Randomized, double-blind; 20 weeks | A composite of thinking tests favoured tesamorelin (P=.03) | NIH-funded; test scores, not daily function |
| Stewart, 2026 | 22 adults aged 55 to 85 | Double-blind, placebo-controlled pilot; 10 weeks | No significant change in thinking, sleep or a walk test; IGF-1 did not rise | Authors raise “insufficient dosing” |
| Clemmons, 2017 | 53 adults with type 2 diabetes | Randomized, double-blind; 12 weeks | Glucose control did not differ from placebo | Sponsor’s trial, run in 2002 |
The developer’s five other phase 2 studies (sleep, vaccination, chronic lung disease, hip surgery) were never published.
Reported in people
In 13 healthy men given tesamorelin for 2 weeks with no comparison group (Stanley, 2011), overnight growth hormone and IGF-1 rose.
Animal studies
In the toxicity studies the FDA summarized, “some animals developed glucose intolerance or severe diabetes, elevated cholesterol levels, increased organ weight, and acromegalic features” (signs of growth hormone excess). In rats, dosing during pregnancy and nursing “resulted in hydrocephaly in offspring”. No lifetime cancer study in rodents has been done.
Lab studies and how it is thought to work
The Egrifta WR label states that tesamorelin “binds and stimulates human GRF receptors with similar potency as the endogenous GRF” (lab studies; GRF is GHRH) and “stimulates growth hormone secretion, and subsequently increases IGF-1 and IGFBP-3 levels” (tested in people).
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. The only doses compared in published trials are 1 mg and 2 mg a day, in two 12-week studies that predate the current products (one in HIV, one in type 2 diabetes), and no published study has compared schedules, times of day or products for effect, so no dose can be called optimal.
Doses tested in people
Every dose below was given under the skin, once a day.
| Study or label | People | Dose | How long |
|---|---|---|---|
| Original Egrifta: the phase 3 trials | Adults with HIV | 2 mg | 26 to 52 weeks |
| Egrifta SV and Egrifta WR: the labels | The approved use | 1.4 mg (SV); 1.28 mg (WR) | No trial behind the approval used these doses |
| Phase 2 (Falutz, 2005) | Adults with HIV | 1 mg or 2 mg (original) | 12 weeks |
| Stanley, 2014 and 2019 | Adults with HIV | 2 mg (original); lowered to 1 mg for three people | 6 and 12 months |
| Ellis, 2025 | Adults with HIV | Paper: “2 mg”, then a newer formulation at a dose it does not give. Registry: “1.4mg” | 6 months |
| Makimura, 2012 | No HIV: obese adults with reduced growth hormone | 2 mg (original); 1 mg if IGF-1 ran high | 12 months |
| NCT03375788 (unpublished) | No HIV: obesity and liver fat | Registry: “2mg daily” and “F4 formulation 1.4mg daily” (F4 is Egrifta SV’s formulation) | 12 months |
| Baker, 2012; Stewart, 2026 | No HIV: older adults | 1 mg (Baker: adjustable, up to 1.5 mg) | 20 and 10 weeks |
| Clemmons, 2017 | No HIV: type 2 diabetes | 1 mg or 2 mg | 12 weeks |
| Stanley, 2011 | No HIV: 13 healthy men | 2 mg | 2 weeks |
Of an unpublished early study of 2 mg once or twice a day in 24 healthy elderly volunteers, the FDA’s review says only that it “suggested that increasing the dose of tesamorelin above 2 mg once daily (QD) could result in increased incidence of AEs” (adverse events). No study in people has tested any product other than the Egrifta formulations, or any route but injection.
Doses in common use
These are amounts in circulation, reported so that a reader can see where each comes from; unless a bullet names a study, no trial set them.
- 2 mg once daily. Telehealth pages and sellers call it “the FDA-approved dose”; a professional HIV reference last updated in 2016, before the current products, also gives it. Studied: it was the original Egrifta’s dose in the phase 3 trials. It is not the dose on either current label.
- “1 mg daily” as a starting or lower dose. Stated by telehealth pages, information sites and a forum summary. Studied in the phase 2 trial in HIV, where the visceral-fat change was not significant, and in three trials outside HIV; no phase 3 trial used it.
- Days off and breaks, such as “5 days on, 2 days off” and “8 weeks on / 8 weeks off”. Stated by clinic and telehealth pages, information sites, a forum summary and a seller of compounded product. Not studied: every trial dosed daily, and none had planned breaks.
- Blends with ipamorelin, such as “1-2 mg tesamorelin + 200 mcg ipamorelin”. Stated by a clinic, information sites and a forum summary. Not studied.
What the pharmacology supports, and what it doesn’t
- Amount (measured in people, then inferred). The labels say 1.4 mg of Egrifta SV and 1.28 mg of Egrifta WR each give blood levels “similar” to 2 mg of the original. So what reaches the blood depends on the formulation; a milligram of a compounded or “research” product has no measured blood level.
- Frequency (measured, then inferred). The drug leaves the blood within minutes (half-lives of 8 minutes on the Egrifta SV label, 11 on Egrifta WR’s), yet one injection a day produced every trial result. The pharmacokinetics give no reason to expect that more than one dose a day is needed, and none was tested for effect; what dosing less often than daily does is unknown. The labels say only “once daily”; one trial gave it “30 minutes before bedtime”, and none has compared times of day.
- Route (measured, then inferred). Only injection has been studied. That a 44-amino-acid peptide taken by mouth would be digested is inference; there are no human data.
- Duration (measured; one claim not confirmed). The effect lasts only while treatment does, and controlled data stop at 52 weeks. The claim that breaks prevent “receptor desensitization” has no tesamorelin data behind it: in the HIV trials IGF-1 stayed raised through 52 weeks of daily dosing.
- Monitoring (the label’s own). The Egrifta WR label tells prescribers to check glucose before and during treatment, to “Monitor IGF-1 levels”, and to weigh continuing when visceral fat has not fallen.
Nobody knows what skipped days or planned breaks do to the effect or to IGF-1, or what blood level any product other than the Egrifta formulations produces.
What common protocols get wrong
- One product’s milligrams applied to another. 2 mg was the dose of the original Egrifta, which its maker says it no longer sells in the United States; the Egrifta WR label says even the two current products “are not substitutable”.
- A schedule borrowed from another drug. A seller of compounded product calls five-days-a-week dosing “borrowed from sermorelin practice”; sermorelin is a different molecule, and when daily tesamorelin stopped, visceral fat returned.
- Amounts above 2 mg a day. A seller of compounded product describes forum protocols of “3 to 4 mg/day, sometimes higher”. The FDA’s review says “EGRIFTA doses above 2mg were not evaluated in the Pivotal Trials”; no trial has reported an effect above 2 mg a day.
The dose is the prescriber’s decision for one patient.
Safety, and who should be most cautious
What is known comes almost entirely from adults with HIV given the original Egrifta: 543 in the 26-week placebo-controlled phases. The label quoted below is Egrifta WR’s, which reports those trials; the newer labels say reactions at their doses “are expected to be similar”.
In the trials. More common on tesamorelin than on placebo in the label’s table: injection-site reactions (17% against 6%), muscle pain (6% against 2%), swelling in the limbs (6% against 2%) and tingling (5% against 2%). Serious adverse events were reported in 3.7% on tesamorelin and 4.2% on placebo.
Blood sugar. The label: “EGRIFTA WR treatment can result in glucose intolerance.” In the phase 3 trials, which excluded people with diabetes, 5% on tesamorelin and 1% on placebo reached an HbA1c of 6.5% or more, the label’s marker of developing diabetes. Later, two people on tesamorelin in the 2019 HIV trial, and two on tesamorelin and one on placebo in the obesity trial without HIV, stopped for high glucose.
IGF-1 and cancer. People with cancer, or a history of it, have the most reason for caution. After 26 weeks, 47% of treated patients had IGF-1 above 2 standard deviation scores, and the label says “The effects of prolonged elevations in IGF-1 levels are unknown.” The risk is theory, reasoned from the growth-promoting action of IGF-1. Cancer was no more frequent than on placebo over 26 weeks (0.9% against 1.1%), but the FDA’s review called the programme “likely of insufficient duration to reliably assess the long-term risk of carcinogenicity”. A later open-label trial in HIV listed two cancers as serious events among 43 people on tesamorelin, and no serious events among 30 untreated.
Allergy and antibodies. Hypersensitivity reactions (itching, redness, flushing, hives, rash) occurred in 4%. Antibodies to tesamorelin were found in 50% after 26 weeks, with no measured loss of effect.
Deaths. The FDA’s review counted 3 deaths on tesamorelin and 1 on placebo in the HIV studies, and 5 and 1 in unpublished studies outside HIV, and concluded “there were too few deaths overall to make any definitive conclusions”.
Long term. The 10-year safety study and the trial of diabetic eye disease that the FDA required at approval were both terminated in 2018, with no results posted. In 2010 the FDA’s review voiced “justified concern for off-label use for indications other than that studied in these trials”.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy, breastfeeding | Contraindicated in pregnancy: it “could result in fetal harm”. The label says not to breastfeed | Label; rat studies |
| Under 18 | Not indicated. The FDA waived studies in children, citing evidence “strongly suggesting” it “would be unsafe in all pediatric age groups” | Label; approval letter |
| Cancer, active or past | Contraindicated in “active malignancy”; the label allows “treated and stable malignancies … only after careful evaluation”. Past cancer was excluded from the approval trials | Label |
| Pituitary disease or surgery, head irradiation or head trauma | Contraindicated | Label |
| Diabetes | Excluded from the phase 3 trials. A 12-week study of 53 people with diabetes, without HIV, found no loss of control | Trials |
| Steroid replacement | Glucocorticoid doses “may require an increase” | Label |
| Other drugs that raise growth hormone | Expected to add to IGF-1, glucose and fluid effects; no combination studied | Theory |
| No HIV | Safety rests on small trials: 29 who started a 12-month trial, 26 in an unpublished one, 78 over 20 weeks and 37 over 12 weeks | Trials |
Product quality
- Compounded tesamorelin. The FDA’s enforcement reports list four recalls of non-Egrifta tesamorelin products, and none of Egrifta: one for “Lack of Assurance of Sterility” (2025), two for “Lack of Processing Controls” (2026) and one for a wrong expiry date (2018).
- “Research use only” tesamorelin. The FDA’s letters to sellers say “injectable drug products can pose risks of serious harm to users”. We found no peer-reviewed laboratory analysis of tesamorelin sold this way. The nearest item is a 2026 preprint, not peer reviewed (Mendias and Awan): of “6441 peptide samples across fourteen compounds”, tesamorelin among them, “41.6% to 71.1% of samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples”; its abstract gives no figure for tesamorelin alone. A seller’s certificate of analysis is not evidence.
What we make of it
This section is our judgment, not a finding.
For adults with HIV and lipodystrophy, tesamorelin, as Egrifta, is an approved medicine with a real and repeatable effect on one measurement: visceral fat on a scan. The effect lasts only as long as treatment does, and what it does for health is, in the FDA’s word, “uncertain”. Against that, more people develop high blood sugar, IGF-1 stays raised, and the long-term safety studies ended without results.
For everyone else, it is unproven and experimental. A benefit on belly fat is plausible: one trial, in abdominally obese adults chosen for low growth hormone, found an effect similar in size to the HIV trials. For the claim to hold, it would have to be repeated in a wider group, with health outcomes and safety followed for years. The other claims run well ahead of the evidence: it is not a weight-loss drug, and no trial result supports the anti-aging or sleep claims.
Every result was earned by the Egrifta products. That a compounded or “research” product performs the same way is an assumption no published study has tested.
For whom, after what, with what monitoring and when to stop are the Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- Trials under way. Egrifta WR with exercise in 100 adults aged 50 to 80 with HIV (NCT06554717); 36 adults after nerve injury (NCT03150511); 120 adults with fatty liver disease, with no HIV requirement (NCT07481734).
- Status. An FDA statement on compounded tesamorelin by name, or a label change.
Common questions
Is tesamorelin FDA-approved?
Yes, but only as the Egrifta products, and only to reduce excess abdominal fat in adults with HIV and lipodystrophy. A product sold as compounded or “research” tesamorelin is not FDA-approved.
Does tesamorelin cause weight loss?
No. The labels say it has “a weight neutral effect”, and in the two main trials, in adults with HIV, weight did not differ from placebo.
Does it reduce belly fat in people who don’t have HIV?
It has been shown to in one trial only: among 60 abdominally obese adults with low growth hormone, those given tesamorelin lost more visceral fat over 12 months than those given placebo, without losing weight. It has not been repeated.
How often is it taken?
In every trial with a result it was given once a day, and the labels say once daily. Schedules such as “5 days on, 2 days off” are stated by clinic, telehealth and seller pages; they are practice that no trial set.
Can a doctor prescribe tesamorelin?
Egrifta SV and Egrifta WR are prescription medicines; of other uses the FDA says providers “generally may prescribe the drug for an unapproved use when they judge that it is medically appropriate”. Of compounding, it says biological products “are not eligible for the exemptions for compounded drugs”; no FDA document we found applies that to compounded tesamorelin by name.
Sources
Show all 37 sourcesHide sources
- EGRIFTA WR (tesamorelin) for injection, prescribing information, SPL version 2. Theratechnologies Inc. / DailyMed (NLM), 2026.
- EGRIFTA SV (tesamorelin) for injection, prescribing information, SPL version 9. Theratechnologies Inc. / DailyMed (NLM), 2026.
- NDA 022505 approval letter, Egrifta (tesamorelin for injection). FDA CDER, 2010.
- NDA 22-505 Summary Review (Division Director memo, Mary H. Parks). FDA CDER, 2010.
- NDA 22-505 Medical Review (Clinical Review, Ali Mohamadi). FDA CDER, 2010.
- Purple Book, October 2026 data. FDA, 2026.
- List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020. FDA, 2020.
- Compounding and the FDA: Questions and Answers. FDA, 2025.
- openFDA NDC directory, generic name tesamorelin. FDA, 2026.
- 21 CFR 600.3. eCFR, 2026.
- 42 U.S.C. 262. U.S. Code, read at Cornell LII, 2026.
- Understanding Unapproved Use of Approved Drugs “Off Label”. FDA, 2018.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list). FDA, 2026.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list). FDA, 2025.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, 2026.
- FDA warning letters, all August 24, 2026: Peptide Partners LLC 735063; Peak Performance Peptides 735127; NuScience Peptides LLC 733652; Royal Peptides LLC 734884; TXP Innovations LLC dba Tex Peptides 735067. FDA, 2026.
- openFDA drug enforcement reports, search “tesamorelin” in product description. FDA, 2026.
- World Anti-Doping Code International Standard: Prohibited List 2026. WADA, 2025.
- The Prohibited List: the 2027 List. WADA, 2026.
- Egrifta: withdrawal of the marketing authorisation application. European Medicines Agency, 2012.
- Annual Information Form dated February 27, 2023. Theratechnologies Inc., 2023.
- ClinicalTrials.gov records: NCT03375788, NCT02572323, NCT01591902, NCT01579695, NCT06554717, NCT03150511, NCT07481734. U.S. National Library of Medicine, 2026.
- A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS, 2005.
- Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007.
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 2008.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes, 2010.
- Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One, 2015.
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014.
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 2019.
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. Journal of Infectious Diseases, 2025.
- Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. Journal of Clinical Endocrinology & Metabolism, 2011.
- Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. Journal of Clinical Endocrinology & Metabolism, 2012.
- Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology, 2012.
- The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci, 2026.
- Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One, 2017.
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org, 2026.
